CA2455896A1 - Utilisation de composes permettant de traiter des affections consecutives a une lesion du nerf corneen apres un lasik ou d'autres traumatismes ou chirurgies de l'oeil - Google Patents

Utilisation de composes permettant de traiter des affections consecutives a une lesion du nerf corneen apres un lasik ou d'autres traumatismes ou chirurgies de l'oeil Download PDF

Info

Publication number
CA2455896A1
CA2455896A1 CA002455896A CA2455896A CA2455896A1 CA 2455896 A1 CA2455896 A1 CA 2455896A1 CA 002455896 A CA002455896 A CA 002455896A CA 2455896 A CA2455896 A CA 2455896A CA 2455896 A1 CA2455896 A1 CA 2455896A1
Authority
CA
Canada
Prior art keywords
compound
injury
surgery
compounds
lasik
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002455896A
Other languages
English (en)
Inventor
Mark R. Hellberg
Iok-Hou Pang
John M. Yanni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2455896A1 publication Critical patent/CA2455896A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des méthodes permettant de traiter des affections consécutives à une lésion du nerf cornéen après un LASIK (kératomileusie in-situ au laser) ou d'autres traumatismes ou chirurgies de l'oeil.
CA002455896A 2001-08-29 2002-07-23 Utilisation de composes permettant de traiter des affections consecutives a une lesion du nerf corneen apres un lasik ou d'autres traumatismes ou chirurgies de l'oeil Abandoned CA2455896A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31565201P 2001-08-29 2001-08-29
US60/315,652 2001-08-29
PCT/US2002/023871 WO2003020281A1 (fr) 2001-08-29 2002-07-23 Utilisation de composes permettant de traiter des affections consecutives a une lesion du nerf corneen apres un lasik ou d'autres traumatismes ou chirurgies de l'oeil

Publications (1)

Publication Number Publication Date
CA2455896A1 true CA2455896A1 (fr) 2003-03-13

Family

ID=23225436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002455896A Abandoned CA2455896A1 (fr) 2001-08-29 2002-07-23 Utilisation de composes permettant de traiter des affections consecutives a une lesion du nerf corneen apres un lasik ou d'autres traumatismes ou chirurgies de l'oeil

Country Status (10)

Country Link
EP (1) EP1420791A4 (fr)
JP (1) JP2005502678A (fr)
CN (1) CN1549718A (fr)
AR (1) AR036194A1 (fr)
BR (1) BR0212151A (fr)
CA (1) CA2455896A1 (fr)
MX (1) MXPA04001255A (fr)
PL (1) PL368565A1 (fr)
WO (1) WO2003020281A1 (fr)
ZA (1) ZA200400837B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091662A1 (fr) * 2003-04-18 2004-10-28 Senju Pharmaceutical Co. Ltd. Agent pour la reparation de la perception corneenne
ES2234428B1 (es) * 2003-12-09 2006-11-01 Universidad Miguel Hernandez Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugia fotorrefractiva.
CN1997381B (zh) * 2004-04-23 2011-06-08 千寿制药株式会社 含有pacap及其衍生物的角膜神经突形成促进剂
JP4932480B2 (ja) * 2004-06-03 2012-05-16 千寿製薬株式会社 アミド化合物を含有する角膜知覚回復剤
US20090082455A1 (en) 2005-03-15 2009-03-26 Ono Pharmaceutical Co. Lted Therapeutic agent for ophthalmic disease
CN113350326B (zh) * 2021-07-28 2023-03-17 爱尔眼科医院集团股份有限公司 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
WO2001085152A2 (fr) * 2000-05-10 2001-11-15 Alcon, Inc. R-eliprodil applique au traitement du glaucome

Also Published As

Publication number Publication date
EP1420791A4 (fr) 2004-09-15
EP1420791A1 (fr) 2004-05-26
MXPA04001255A (es) 2004-05-27
ZA200400837B (en) 2005-02-02
AR036194A1 (es) 2004-08-18
JP2005502678A (ja) 2005-01-27
CN1549718A (zh) 2004-11-24
BR0212151A (pt) 2004-08-24
WO2003020281A1 (fr) 2003-03-13
PL368565A1 (en) 2005-04-04

Similar Documents

Publication Publication Date Title
US7625864B2 (en) Methods and compositions for treating ocular disorders
WO2007101204A1 (fr) Méthode de traitement du glaucome
JPH10507743A (ja) 薬剤投与のための方法と手段
DE69924284T2 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
CA2455896A1 (fr) Utilisation de composes permettant de traiter des affections consecutives a une lesion du nerf corneen apres un lasik ou d'autres traumatismes ou chirurgies de l'oeil
US20040162315A1 (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma
JP2016026229A (ja) Ｂｄｎｆ（脳由来神経栄養因子）をベースとする眼科用製剤およびそれらの使用
AU1506600A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
WO2003004058A1 (fr) Agents de protection du nerf optique contenant un bloqueur de recepteur $g(a)1 en tant qu'ingredient actif
AU2002322700A1 (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
US20050203121A1 (en) Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
EP1859795A1 (fr) Agent therapeutique pour les maladies ophtalmiques
EP1948217A2 (fr) Utilisation du facteur de croissance du nerf dans des gouttes ophtalmiques pour le traitement de pathologies du systeme nerveux central telles que la maladie d'alzheimer et la maladie de parkinson
JP2004331502A (ja) 視神経細胞保護剤
MXPA01002895A (en) Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
JP4393863B2 (ja) 視神経細胞保護剤
EP1169026B1 (fr) Utilisation d'activateurs ap-1 pour le traitement du glaucome et de l'hypertension oculaire
KR20070019001A (ko) 안구 신경퇴행성 질환의 치료를 위한 신경성 인자 자극제

Legal Events

Date Code Title Description
FZDE Dead